Last reviewed · How we verify
Induction of neural stem cells
At a glance
| Generic name | Induction of neural stem cells |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (PHASE3)
- The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders (PHASE1)
- The Safety and Efficacy of NouvSoma001 in Ischemic Stroke (PHASE1)
- Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease (PHASE1, PHASE2)
- The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease (PHASE1)
- Baker Gordon Syndrome Natural History Study
- A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease (PHASE1)
- Cognitive Flexibility in Depression and TMS Response (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: